ClinicalTrials.gg
CompletedNCT05255991TETON-2Updated Oct 15, 2026Results posted

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of Placebo and Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease, sponsored by United Therapeutics. Completed at 108 sites in 16 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
597
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France — 10 open to participants now, 16 under way, 5 of them phase 3. Idiopathic Pulmonary Fibrosis · France.

Enrollment
9th of 57
597 · median 178
Started
2022
with 6 others
Phase 3
16 of 70
3 open now
Registered
45th of 70
by date

Among the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, this one is the 9th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2022, is one of 16 in phase 3, and was the 45th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

10 of the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, or all of them as a file.
02

Study summary

Study RIN-PF-303 is a multinational study designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.

Read the detailed description

Study RIN-PF-303 is a multinational, randomized, double-blind, placebo-controlled study to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute FVC in subjects with idiopathic pulmonary fibrosis (IPF) over a 52-week period. Subjects will be randomly allocated 1:1 to receive inhaled treprostinil or placebo. All subjects will initiate inhaled treprostinil or placebo at a dose of 3 breaths administered 4 times daily (QID) and will titrate to a target dosing regimen of 12 breaths QID. Study drug doses may be titrated up as tolerated, until the target dose or maximum clinically tolerated dose is achieved. Once eligible, 6 Treatment Period visits to the clinic will be required at Weeks 4, 8, 16, 28, 40, and 52.

Efficacy assessments include spirometry (FVC), time to clinical worsening, time to first acute exacerbation of IPF, overall survival, King's Brief Interstitial Lung Disease (K-BILD) questionnaire, plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration, supplemental oxygen use, and lung diffusion capacity (DLCO). Safety assessments include the development of adverse events (AEs)/serious adverse events (SAEs), vital signs, clinical laboratory parameters, and electrocardiogram (ECG) parameters.

Subjects who complete the Week 52 Visit may be offered the opportunity to enter an open-label extension (OLE) study after completing the final study visit.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject gives voluntary to participate in the study.
  2. Subject is ≥40 years of age, inclusive, at the time of signing informed consent.
  3. The subject has a diagnosis of IPF based on the 2018 ATS/ERS/JRS/ALAT Clinical Practice Guideline (Raghu 2018) and confirmed by central review of high-resolution computed tomography (HRCT) (performed within the previous 12 months), and if available, surgical lung .
  4. FVC ≥45% predicted at Screening.
  5. Subjects on pirfenidone or nintedanib must be on a stable and optimized dose for ≥30 days prior to Baseline. Concomitant use of both pirfenidone and nintedanib is not permitted.
  6. Women of must be non-pregnant (as confirmed by a urine pregnancy test at Screening and Baseline) and non-lactating, and will abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of for the duration of the study, and at least 30 days after discontinuing study drug.
  7. Males with a partner of childbearing potential must use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug.
  8. In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or lactating.
  2. Subject has primary obstructive airway physiology: /FVC \<0.70 at Screening.
  3. The subject has shown intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  4. The subject has received any PAH-approved therapy, including prostacyclin therapy (epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), IP receptor agonists (selexipag), endothelin receptor antagonists, phosphodiesterase type 5 inhibitors (PDE5-Is), or soluble guanylate cyclase stimulators within 60 days prior to Baseline. As needed use of a PDE5-I for erectile dysfunction is permitted, provided no doses are taken within 48 hours of any study-related efficacy assessments.
  5. Use of any of the following medications: azathioprine (AZA), cyclosporine, mycophenolate mofetil, tacrolimus, oral (OCS) >20 mg/day or the combination of OCS+AZA+N-acetylcysteine within 30 days prior to Baseline; cyclophosphamide within 60 days prior to Baseline; or rituximab within 6 months prior to Baseline.
  6. The subject is receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  7. Exacerbation of IPF or active pulmonary or upper respiratory infection within 30 days prior to Baseline. Subjects must have completed any antibiotic or steroid regimens for treatment of the infection or acute exacerbation more than 30 days prior to Baseline to be eligible. If hospitalized for an acute exacerbation of IPF or a pulmonary or upper respiratory infection, subjects must have been discharged more than 90 days prior to Baseline to be eligible.
  8. Uncontrolled cardiac disease, defined as myocardial infarction within 6 months prior to Baseline or unstable angina within 30 days prior to Baseline.
  9. In the opinion of the Investigator, the subject has any condition that would interfere with the interpretation of study assessments or would impair study participation or cooperation.
  10. Use of any other drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement) within 30 days prior to Screening. Subjects participating in non-interventional, observational, or registry studies are eligible.
  11. \<6 months due to IPF or a concomitant illness.
  12. Acute pulmonary embolism within 90 days prior to Baseline.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
597 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo inhaled using an ultrasonic nebulizer QID

    Drug: Placebo · Device: Treprostinil Ultrasonic Nebulizer

  • Experimental
    Inhaled Treprostinil

    Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled QID and titrated up to a target of 12 breaths QID or until the subject reaches their maximum clinically tolerated dose.

    Drug: Inhaled Treprostinil · Device: Treprostinil Ultrasonic Nebulizer

Interventions

  • DrugPlacebo

    Placebo administered QID

  • Inhaled treprostinil (6 mcg/breath) administered QID

    Also known as: Tyvaso

  • DeviceTreprostinil Ultrasonic Nebulizer

    Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

06

What researchers measure

Primary outcomes

  1. Change in Absolute FVC From Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Time to Clinical Worsening

    Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

    Time frame: Baseline to Week 52

  2. Time to First Acute Exacerbation of IPF

    An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

    Time frame: Baseline to Week 52

  3. Overall Survival at Week 52

    Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).

    Time frame: Baseline to Week 52

  4. Change in % Predicted FVC From Baseline to Week 52

    The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.

    Time frame: Baseline to Week 52

  5. Change in K-BILD Total Score From Baseline to Week 52

    The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.

    Time frame: Baseline to Week 52

  6. Change in DLCO From Baseline to Week 52

    The DLCO measurement measures how well oxygen moves from the lungs to the blood.

    Time frame: Baseline to Week 52

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneInhaled TreprostinilPlacebo
Started298295
Completed224239
Not completed7456
Withdrew: Adverse event1410
Withdrew: Death1421
Withdrew: Lost to follow-up10
Withdrew: Physician decision32
Withdrew: Withdrawal by subject3418
Withdrew: Lung transplantation43
Withdrew: Progressive disease42

Outcome measures

PrimaryChange in Absolute FVC From Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

Time frame:
Baseline to Week 52
Reported as:
Median · mL
Change in Absolute FVC From Baseline to Week 52
mLInhaled TreprostinilPlacebo
Change in Absolute FVC From Baseline to Week 52-49.9 (-79.2 to -19.5)-136.4 (-172.5 to 104.0)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = <0.0001 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 95.6 · 95% CI 52.2 to 139.0Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryTime to Clinical Worsening

Clinical worsening was monitored from randomization until 1 of the following criteria were met: death (all causes), hospitalization due to a respiratory indication, or 10% relative decline in % predicted FVC. The number of participants with clinical worsening was reported. The time to first clinical worsening event was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Time to Clinical Worsening
ParticipantsInhaled TreprostinilPlacebo
Time to Clinical Worsening81115
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.0191 (P-value was calculated with log-rank test stratified by baseline background therapy category.) · Hazard ratio (hr): 0.71 · 95% CI 0.53 to 0.95P-value was 0.0190 for the proportional hazard model. Hazard ratio, 95% confidence interval (CI), and P-values were calculated with proportional hazards model with treatment and baseline background therapy as explanatory variables.
SecondaryTime to First Acute Exacerbation of IPF

An acute exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality. The number of participants with an exacerbation of IPF was reported. The time to first acute exacerbation of IPF was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Time to First Acute Exacerbation of IPF
ParticipantsInhaled TreprostinilPlacebo
Time to First Acute Exacerbation of IPF917
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.1298 (P-value was calculated with log-rank test stratified by baseline background therapy category.) · Hazard ratio (hr): 0.54 · 95% CI 0.24 to 1.22P-value was 0.1368 for the proportional hazard model. Hazard ratio, 95% confidence interval (CI), and P-values were calculated with proportional hazards model with treatment and baseline background therapy as explanatory variables.
SecondaryOverall Survival at Week 52

Vital status was assessed for all subjects at Week 52, including those who discontinued the study prematurely. The number of deaths by Week 52 was reported. The time to death was analyzed by stratified log-rank test (p-value) and presented with the hazard ratio calculated by proportional hazards model with treatment and baseline background therapy as explanatory variables. Note: Participants who discontinued from the study early had their time to death censored at Day 373 or last contact date when known to be alive (whichever occurred first), and participants with lung transplantation had their time to death censored at lung transplant date. Therefore, the number of deaths for this outcome measure differ from the overall number on deaths (reported in the Adverse Events section).

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Overall Survival at Week 52
ParticipantsInhaled TreprostinilPlacebo
Overall Survival at Week 521924
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Log Rank · p = 0.3907 (P-value was calculated with log-rank test stratified by baseline background therapy category.) · Hazard ratio (hr): 0.77 · 95% CI 0.42 to 1.41P-value was 0.3986 for the proportional hazard model. Hazard ratio, 95% confidence interval (CI), and P-values were calculated with proportional hazards model with treatment and baseline background therapy as explanatory variables.
SecondaryChange in % Predicted FVC From Baseline to Week 52

The FVC measurement indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath. Percent predicted FVC is calculated based on factors such as ethnicity, sex, age, height, and weight.

Time frame:
Baseline to Week 52
Reported as:
Median · percentage of predicted
Change in % Predicted FVC From Baseline to Week 52
percentage of predictedInhaled TreprostinilPlacebo
Change in % Predicted FVC From Baseline to Week 52-1.4 (-2.2 to -0.5)-3.8 (-4.8 to -3.1)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = <0.0001 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 2.7 · 95% CI 1.5 to 4.0Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryChange in K-BILD Total Score From Baseline to Week 52

The King's Brief Interstitial Lung Disease Questionnaire (K-BILD) is a self-administered, 15-item questionnaire validated for patients with interstitial lung disease (ILD) consisting of 3 domains (breathlessness and activities, psychological, and chest symptoms). Each of the 15 questions is scored from 1 (worst score) to 7 (best score). The scores for the 15 questions are added together and converted into a Total Score from 0 to 100. Higher scores indicate a better quality of life.

Time frame:
Baseline to Week 52
Reported as:
Median · scores on a scale
Change in K-BILD Total Score From Baseline to Week 52
scores on a scaleInhaled TreprostinilPlacebo
Change in K-BILD Total Score From Baseline to Week 52-1.0 (-1.9 to 0.0)-2.6 (-3.7 to -0.8)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = 0.0124 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 2.29 · 95% CI 0.50 to 4.08Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.
SecondaryChange in DLCO From Baseline to Week 52

The DLCO measurement measures how well oxygen moves from the lungs to the blood.

Time frame:
Baseline to Week 52
Reported as:
Median · mmol/min/kPa
Change in DLCO From Baseline to Week 52
mmol/min/kPaInhaled TreprostinilPlacebo
Change in DLCO From Baseline to Week 52-0.2 (-0.3 to -0.1)-0.3 (-0.4 to -0.2)
Statistical analysis
  • Inhaled Treprostinil vs Placebo · Aligned Rank Stratified Wilcoxon · p = 0.0309 (P-value was obtained from the aligned rank stratified Wilcoxon test with background therapy as strata.) · Treatment difference: 0.15 · 95% CI 0.01 to 0.29Hodges-Lehmann location-shift estimate of the overall treatment difference with 95% CI was reported.

Adverse events

Collected over Adverse events (AEs) were recorded throughout the course of the study from the time that each subject signed the ICF until the time screen failure was documented; until the subject withdrew consent and discontinued from the study; or until resolution, until judged by the Investigator to no longer be clinically significant, or for at least 30 days beyond the final study visit at Week 52 for up to an average of 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Treprostinil21/298 (7%)75/298 (25.2%)268/298 (89.9%)
Placebo25/295 (8.5%)68/295 (23.1%)259/295 (87.8%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventInhaled TreprostinilPlacebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders12/29822/295
PneumoniaInfections and infestations7/29813/295
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2984/295
Respiratory failureRespiratory, thoracic and mediastinal disorders3/2984/295
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/2984/295
Respiratory tract infectionInfections and infestations4/2980/295
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/2981/295
Acute myocardial infarctionCardiac disorders3/2983/295
InfluenzaInfections and infestations3/2980/295
Cardiac failure congestiveCardiac disorders1/2982/295
Most frequent other events
Showing 10 of 21
Most frequent other events
EventInhaled TreprostinilPlacebo
CoughRespiratory, thoracic and mediastinal disorders144/29871/295
HeadacheNervous system disorders59/29835/295
DiarrhoeaGastrointestinal disorders41/29850/295
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders28/29837/295
DyspnoeaRespiratory, thoracic and mediastinal disorders36/29831/295
BronchitisInfections and infestations30/29830/295
NasopharyngitisInfections and infestations25/29830/295
DizzinessNervous system disorders29/29819/295
NauseaGastrointestinal disorders24/29826/295
COVID-19Infections and infestations25/29822/295

Baseline characteristics

Age, Continuous
Age, Continuous(years)Inhaled TreprostinilPlaceboTotal
Median73.0 (41 to 91)72.0 (50 to 88)72.0 (41 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled TreprostinilPlaceboTotal
Female6058118
Male238237475
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Inhaled TreprostinilPlaceboTotal
American Indian or Alaska Native000
Asian313970
Native Hawaiian or Other Pacific Islander011
Black or African American011
White262235497
More than one race011
Unknown or Not Reported51823
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Inhaled TreprostinilPlaceboTotal
Hispanic or Latino8574159
Not Hispanic or Latino202203405
Unknown or Not Reported111829
Time Since IPF Diagnosis
Time Since IPF Diagnosis(years)Inhaled TreprostinilPlaceboTotal
Median3.375 (0.09 to 19.31)3.250 (0.07 to 15.23)3.310 (0.07 to 19.31)
Background Therapy at Randomization
Background Therapy at Randomization(Participants)Inhaled TreprostinilPlaceboTotal
No Background Therapy7373146
Nintedanib105109214
Pirfenidone120113233
Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC)(mL)Inhaled TreprostinilPlaceboTotal
Median2656.5 (1059 to 5487)2650.0 (975 to 5035)2652.0 (975 to 5487)
% Predicted FVC
% Predicted FVC(percentage of predicted)Inhaled TreprostinilPlaceboTotal
Median75.40 (41.0 to 129.9)75.80 (42.6 to 136.6)75.60 (41.0 to 136.6)

4 further baseline measures are reported on the registry.

08

Study locations

108 sites
  • CINME S.A. - Centro de Investigaciones Metabolicas
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1027AAP, Argentina
  • Centro Medico Dra. De Salvo
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
  • Instituto Ave Pulmo - Fundación enfisema
    Mar del Plata, Buenos Aires 7600, Argentina
  • Sanatorio Allende S.A.
    Córdoba, Córdoba Province 5021, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, Córdoba Province 5800, Argentina
  • Centro Médico INSARES
    Mendoza, Mendoza Province 5500, Argentina
  • Sanatorio Parque - Consultorios Externos
    Rosario, Santa Fe Province 2000, Argentina
  • Centro Integral de Medicina Respiratoria
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Investigaciones en Patologías Respiratorias
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Royal Prince Alfred Hospital, Missenden Road
    Camperdown, New South Wales 2050, Australia
  • Macquarie University
    Macquarie Park, New South Wales 2109, Australia
  • Westmead Hospital, Corner of Hawkesbury and Darcy Road
    Westmead, New South Wales 2145, Australia
  • Cairns Hospital
    Cairns, Queensland 5870, Australia
  • Lung Research Qld
    Chermside, Queensland 4032, Australia
  • Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Mater Misericordiae Ltd
    South Brisbane, Queensland 4101, Australia
  • Respiratory Clinical Trials Pty Ltd
    Kent Town, South Australia 5067, Australia
  • Alfred Health
    Melbourne, Victoria 3004, Australia
  • Austin Health
    Melbourne, Victoria 3004, Australia
  • Institute for Respiratory Health - Midland
    Nedlands, Western Australia 6009, Australia
  • Institute for Respiratory Health - Nedlands
    Nedlands, Western Australia 6009, Australia
  • Hôpital Erasme
    Anderlecht, Brussels Capital 1070, Belgium
  • CHU UCL Namur asbl - Site Godinne
    Yvoir, Namur 5530, Belgium
  • AZORG vzw
    Aalst, 9300, Belgium
  • Ziekenhuis Aan de Stroom
    Antwerp, 2020, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHR de la Citadelle
    Liège, 4000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • Centro de Investigacion del Maule SpA
    Talca, Maule Region 3465586, Chile
  • Instituto Nacional Torax
    Santiago, Santiago Metropolitan 7500691, Chile
  • Fundación Médica San Cristobal
    Santiago, Santiago Metropolitan 7630000, Chile
  • Oncocentro APYS
    Viña del Mar, Valparaiso 2520598, Chile
  • Aarhus University Hospital - Department of Respiratory Diseases and Allergy, Research Unit
    Aarhus N, 8200, Denmark
  • Gentofte Hospital - Lungemedicinsk forskning
    Hellerup, 2900, Denmark
  • Odense University Hospital - Department of Respiratory Medicine J.
    Odense C, 5000, Denmark
  • Hôpital Pontchaillou
    Rennes, Ille-et-Vilaine 35033, France
  • Hôpital Avicenne
    Bobigny, Seine-Saint Denis 93000, France
  • CHU Amiens Picardie Site Sud - Service de Pneumologie
    Amiens, 80054, France
  • Hopital Cote de Nacre
    Caen, 14033, France
  • Groupement Hospitalier EST, Service de Pneumologie
    Lyon, 69677 Cedex, France
  • APHM-Hôpital Nord
    Marseille, 13015, France
  • Service de Pneumologie, Hôpital Européen Georges Pompídou (HEGP)
    Paris, 75015, France
  • Hôpital Bichat
    Paris, 75018, France
  • CHU Reims - Hôpital Maison Blanche
    Reims, 51092, France
  • Hôpital Charles Nicolle-1 Rue de Germont
    Rouen, 76000, France
  • CHU de Rouen - Hôpital Charles Nicolle
    Rouen, 76031, France
  • Hôpital Larrey
    Toulouse, 31059, France
  • CHRU Tours - Hôpital Bretonneau
    Tours, 37044, France
  • Klinik Löwenstein GmbH
    Löwenstein, Baden-Wurttemberg 74245, Germany
  • RoMed Klinikum Rosenheim
    Rosenheim, Bavaria 83022, Germany
  • Universitätsmedezin Essen Ruhrlandklinik Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, North Rhine-Westphalia 45239, Germany
  • Zentralklinik Bad Berka GmbH
    Bad Berka, 99437, Germany
  • Fachkrankenhaus Coswig
    Coswig, 01640, Germany
  • LMU Klinikum der Universität
    München, 81377, Germany
  • Meir Medical Center
    Kfar Saba, Central District 44281, Israel
  • Kaplan Medical Center
    Rehovot, Central District 76100, Israel
  • Lady Davis Carmel Medical Center
    Haifa, Haifa District 34362, Israel
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalem 9103102, Israel
  • Hadassah Medical Center - PPDS
    Jerusalem, Jerusalem 91120, Israel
  • Tel Aviv Sourasky Medical Center - PPDS
    Tel Aviv, Southern District 64239, Israel
  • Sheba Medical Center - PPDS
    Ramat Gan, Tel Aviv 52621, Israel
  • Hillel Yaffe Medical Center
    Hadera, 38100, Israel
  • Rambam Medical Center - PPDS
    Haifa, 3109601, Israel
  • Rabin Medical Center - PPDS
    Petah Tikva, 4910000, Israel
  • Presidio Ospedaliero GB Morgagni L Pierantoni
    Forlì, Emilia-Romagna 47121, Italy
  • Ospedale S. Giuseppe Multimedica
    Milan, Lombardy 20123, Italy
  • Azienda Ospedaliero Universitaria Policlinico "G.Rodolico-San Marco"
    Catania, Sicily 95123, Italy
  • Azienda Ospedaliera Universitaria Senese
    Siena, Tuscany 53100, Italy
  • Azienda Ospedaliero-Universitaria delle Marche
    Ancona, 60126, Italy
  • Azienda Ospedaliero Universitaria Di Modena Policlinico
    Modena, 41124, Italy
  • Fondazione Policlinico Universitario A Gemelli-Rome
    Roma, 00168, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Rome, 00133, Italy
  • Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas
    Mexico City, Mexico City 14080, Mexico
  • Unidad de Investigación Clínica en Medicina, S.C.
    Monterrey, Nuevo León 64060, Mexico
  • Hospital Universitario "Dr. José Eleuterio González"
    Monterrey, Nuevo León 64460, Mexico
  • Zuyderland Medisch Centrum
    Heerlen, Limburg 6419 PC, Netherlands
  • Erasmus MC
    Rotterdam, South Holland 3015 GD, Netherlands
  • St. Antonius Ziekenhuis
    Nieuwegein, Utrecht 3435 CM, Netherlands
  • Canterbury Respiratory Research Group
    Christchurch, Canterbury 8013, New Zealand
  • Respiratory Medicine
    Hamilton, Waikato Region 3204, New Zealand
  • Hospital Nacional Adolfo Guevara Velasco
    Cusco, Departamento de Cusco 8003, Peru
  • Clinica Ricardo Palma
    Lima, Lima Province 15036, Peru
  • Hospital de Chancay y Servicios Basicos deSalud
    Huaral, Lima region 15131, Peru
  • Hospital Central de la Fuerza Aerea Del Peru
    Lima, 15046, Peru
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggido 13496, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggido 13620, South Korea
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, South Korea
  • SMG - SNU Boramae Medical Center
    Seoul, Seoul Teugbyeolsi 7061, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • The Catholic University of Korea - Eunpyeong St. Mary's Hospital
    Seoul, 03312, South Korea
  • Samsung Medical Center - PPDS
    Seoul, 06351, South Korea
  • Hospital Universitario Son Espases
    Palma de Mallorca, Balearic Islands 07120, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Barcelona 08036, Spain
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Universitario Virgen de Las Nieves
    Granada, Granada 18014, Spain
  • Hospital Universitario de La Princesa
    Madrid, Madrid 28006, Spain

Showing the first 100 of 108 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Nathan SD, Smith P, Deng C, Golden J, Reynaud-Gaubert M, Farr G, Bregman B, Crossno PF, Harari S, Gupta N, Jouneau S, Adir Y, Molina-Molina M, Breytenbach N, Peterson L, Bell H, Zywot E, Rao Y, Flaherty KR, Cottin V, Behr J; TETON-1 and TETON-2 Trial Investigators. Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2026 Sep 23:aamag507. doi: 10.1093/ajrccm/aamag507. Online ahead of print. PubMed 42776606 ↗
  • Nathan SD, Smith P, Deng C, De Salvo M, Wuyts W, Pavie-Gallegos J, Song JW, Kramer MR, King CS, Mackintosh JA, Chambers D, Miranda GV, Breytenbach N, Peterson L, Bell H, Flaherty KR, Behr J, Cottin V; TETON-2 Trial Investigators. Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. N Engl J Med. 2026 Jul 9;395(2):127-137. doi: 10.1056/NEJMoa2512911. Epub 2026 Mar 11. PubMed 41812190 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jun 2025, 33 months.

Results were first posted in Oct 2026, 1 year 3 months after primary completion.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 33 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2022 → Sep 2022, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 25, 2022
StartActual
Sep 12, 2022was Oct 2022
Primary completionActual
Jun 30, 2025
CompletionActual
Jun 30, 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital Nacional Adolfo Guevara Velasco · Cusco, Peru
Show 1 removed
  • Hospital Nacional Adolfo Guevara Velasco · Wanchaq, Peru
Oct 15, 2026
Start date
Oct 4, 2022→Sep 12, 2022
Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in Absolute FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
Oct 15, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42776606 ↗
Oct 15, 2026
Secondary outcomes
3 edited, 3 description edited
What changed in the outcomes
  • EditedChange in % Predicted FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • EditedChange in K-BILD QuestionnaireTotal Score fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • EditedChange in DLCO fromFrom Baseline to Week 52Time frame: Baseline to Week 52
  • DescriptionOverall Survival at Week 52: how it is measured was reworded
  • DescriptionTime to Clinical Worsening: how it is measured was reworded
  • DescriptionTime to First Acute Exacerbation of IPF: how it is measured was reworded
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42776606 ↗
    1 site added, 1 site removed
    Show site
    • Hospital Nacional Adolfo Guevara Velasco · Cusco, Peru
    Show 1 removed
    • Hospital Nacional Adolfo Guevara Velasco · Wanchaq, Peru
    Start date Oct 4, 2022→Sep 12, 2022
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in Absolute FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    Secondary outcomes 3 edited, 3 description edited
    What changed in the outcomes
    • EditedChange in % Predicted FVC fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • EditedChange in K-BILD QuestionnaireTotal Score fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • EditedChange in DLCO fromFrom Baseline to Week 52Time frame: Baseline to Week 52
    • DescriptionOverall Survival at Week 52: how it is measured was reworded
    • DescriptionTime to Clinical Worsening: how it is measured was reworded
    • DescriptionTime to First Acute Exacerbation of IPF: how it is measured was reworded
    + 7 other changes: identifiers, verification date, oversight details, description, conditions, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05255991
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Sep 12, 2022
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion